![Thierry Bardon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thierry Bardon
Director/Board Member at Aterovax SA
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Isabelle de Baillenx | F | - |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | 23 years |
Gérald Ulrich | M | - |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | - |
Luc Dohan | M | - |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | - |
Benoît Pastour | M | 61 |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | 11 years |
Antoine Ferry | M | 64 |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | 17 years |
Eric Viaud | M | 65 |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | 18 years |
Michel Datchary | M | 72 |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | 10 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jean-Paul Villot | M | 78 |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | 6 years |
Jean-Pierre Mollet | M | - |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | - |
Vladimir Bolze | M | - |
FA Dièse SAS
![]() FA Dièse SAS Investment ManagersFinance FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds. | 8 years |
Emmanuel Valentin | M | - |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | 9 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 11 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thierry Bardon
- Personal Network